Global and United States Androgen Receptor Antagonist Market Report & Forecast 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global and United States Androgen Receptor Antagonist Market Report & Forecast 2024-2034
Androgen receptor (AR) is an important target of prostate cancer drugs, and its structure plays an important guiding role in drug development. The androgen receptor consists of 4 structural domains and 8 exons, which are N-terminal binding domain (NTD, exon 1), DNA binding domain (DBD, exon 2-3), hinge region ( HR, exon 4), C-terminal binding domain (LBD, exons 5-8), nuclear localization signal (NLS) is a dichotomous motif contained within exons 3 and 4. The LBD contains a buried hormone-binding pocket (HBP) and a transcriptional activation domain, AF2. AF2 plays an important role in the formation of homodimers, AF2 contains helices 3, 4, 5 and 12 (H3, H4, H5, H12), H12 can change position when ligand binds, when ligand binds to the binding pocket Upon binding, H12 folds back closer to the binding site, preventing ligand disengagement. Non-steroidal AR antagonists avoid the common hormone-like toxic side effects of steroidal AR antagonists, expand clinical applications, and are currently the most commonly used prostate cancer drugs in the United States.
Market Analysis and InsightsGlobal and United States Androgen Receptor Antagonist Market
This report focuses on global and United States Androgen Receptor Antagonist market, also covers the segmentation data of other regions in regional level and county level.
The global Androgen Receptor Antagonist revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In United States the Androgen Receptor Antagonist revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Androgen Receptor Antagonist include Merck & Co., Inc, Sanofi, Astellas Pharma Inc, Pfizer, Johnson & Johnson, Bayer, Hinova, Jiangsu Hengrui Pharmaceuticals Co., Ltd and Kintor Pharma, etc. The global five biggest players hold a share of % in 2024.
Global Androgen Receptor Antagonist Scope and Market Size
Androgen Receptor Antagonist market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Androgen Receptor Antagonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Androgen Receptor Antagonist market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.

Merck & Co., Inc
Sanofi
Astellas Pharma Inc
Pfizer
Johnson & Johnson
Bayer
Hinova
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Kintor Pharma
Segment by Type
First Generation Inhibitors
Second Generation Inhibitors
Prostate Cancer
Breast Cancer
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter 1Introduces Androgen Receptor Antagonist definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Androgen Receptor Antagonist companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Androgen Receptor Antagonist in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Androgen Receptor Antagonist sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
Market Analysis and InsightsGlobal and United States Androgen Receptor Antagonist Market
This report focuses on global and United States Androgen Receptor Antagonist market, also covers the segmentation data of other regions in regional level and county level.
The global Androgen Receptor Antagonist revenue was US$ million in 2024 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period (2024-2034).
In United States the Androgen Receptor Antagonist revenue is expected to grow from US$ million in 2024 to US$ million by 2034, at a CAGR of % during the forecast period (2024-2034).
The global key players of Androgen Receptor Antagonist include Merck & Co., Inc, Sanofi, Astellas Pharma Inc, Pfizer, Johnson & Johnson, Bayer, Hinova, Jiangsu Hengrui Pharmaceuticals Co., Ltd and Kintor Pharma, etc. The global five biggest players hold a share of % in 2024.
Global Androgen Receptor Antagonist Scope and Market Size
Androgen Receptor Antagonist market is segmented in regional and country, by players, by type and by application. Companies, stakeholders, and other participants in the global Androgen Receptor Antagonist market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by type and by application for the period 2018-2034.
For United States market, this report focuses on the Androgen Receptor Antagonist market size by players, by Type and by Application, for the period 2018-2034. The key players include the global and local players, which play important roles in United States.

By Company
Merck & Co., Inc
Sanofi
Astellas Pharma Inc
Pfizer
Johnson & Johnson
Bayer
Hinova
Jiangsu Hengrui Pharmaceuticals Co., Ltd
Kintor Pharma
Segment by Type
First Generation Inhibitors
Second Generation Inhibitors
Segment by Application
Prostate Cancer
Breast Cancer
Other
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa
Chapter Introduction
Chapter 1Introduces Androgen Receptor Antagonist definition, global sales (volume and revenue), United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the volume, price, revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue, price, volume, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Androgen Receptor Antagonist companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Revenue and volume of Androgen Receptor Antagonist in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 6Americas by type, by application and by country, sales, and revenue for each segment.
Chapter 7EMEA by type, by application and by region, sales, and revenue for each segment.
Chapter 8China by type, by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, sales, and revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Androgen Receptor Antagonist sales, revenue, gross margin, and recent development, etc.
Chapter 11Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 12Research findings and conclusion
